Aduro Biotech Inc. (NASDAQ:ADRO) insider Jennifer Lew sold 6,360 shares of Aduro Biotech stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $14.95, for a total transaction of $95,082.00. Following the sale, the insider now owns 48,955 shares of the company’s stock, valued at approximately $731,877.25. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Aduro Biotech Inc. (NASDAQ:ADRO) traded up 2.91% on Friday, hitting $15.22. 56,435 shares of the stock traded hands. Aduro Biotech Inc. has a 1-year low of $7.26 and a 1-year high of $34.95. The stock has a 50-day moving average price of $14.75 and a 200 day moving average price of $13.16. The company’s market cap is $985.56 million.
Aduro Biotech (NASDAQ:ADRO) last posted its earnings results on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.21. The firm earned $39 million during the quarter, compared to analysts’ expectations of $25.24 million. Aduro Biotech had a negative net margin of 23.69% and a negative return on equity of 9.23%. The business’s revenue for the quarter was up 306.3% compared to the same quarter last year. On average, analysts anticipate that Aduro Biotech Inc. will post ($1.39) EPS for the current fiscal year.
ADRO has been the subject of a number of analyst reports. FBR & Co restated a “buy” rating on shares of Aduro Biotech in a report on Monday, June 6th. Roth Capital restated a “buy” rating and set a $22.00 price objective on shares of Aduro Biotech in a report on Monday, July 11th. Zacks Investment Research cut shares of Aduro Biotech from a “hold” rating to a “sell” rating in a report on Monday, July 18th. Finally, Canaccord Genuity restated a “buy” rating and set a $30.00 price objective on shares of Aduro Biotech in a report on Friday, August 5th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $22.00.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Aduro Biotech by 15.3% in the second quarter. Vanguard Group Inc. now owns 1,794,838 shares of the company’s stock worth $20,300,000 after buying an additional 237,924 shares during the period. BlackRock Fund Advisors raised its position in shares of Aduro Biotech by 62.0% in the second quarter. BlackRock Fund Advisors now owns 1,665,187 shares of the company’s stock worth $18,833,000 after buying an additional 637,486 shares during the period. Franklin Resources Inc. raised its position in shares of Aduro Biotech by 0.6% in the first quarter. Franklin Resources Inc. now owns 893,210 shares of the company’s stock worth $11,442,000 after buying an additional 5,527 shares during the period. State Street Corp raised its position in shares of Aduro Biotech by 237.9% in the second quarter. State Street Corp now owns 543,514 shares of the company’s stock worth $6,147,000 after buying an additional 382,654 shares during the period. Finally, BVF Inc. IL acquired a new position in shares of Aduro Biotech during the second quarter worth about $5,809,000. Institutional investors and hedge funds own 29.76% of the company’s stock.
About Aduro Biotech
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.